[1]
|
Molthoff CF, Klabbers BM, Berkhof J, et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-〔18F〕fluoro-D-glucose(FDG)and 3′-〔18F〕fluoro-3′-deoxythymidine(FLT). Mol Imaging Biol, 2007, 9(6): 340-347. doi: 10.1007/s11307-007-0104-5 |
[2]
|
Agool A, Slart RH, Thorp KK, et al. Effect of radiotherapy and chemotherapy on bone marrow activity: a18F-FLT-PET study. Nucl Med Commun, 2011, 32(1): 17-22. doi: 10.1097/MNM.0b013e328340798c |
[3]
|
Yue J, Chen L, Cabrera AR, et al. Measuring tumor cell proliferation with18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med, 2010, 51(4): 528-534. doi: 10.2967/jnumed.109.072124 |
[4]
|
Menda Y, Laura L, Dornfeld K, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine(18F-FLT)in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med, 2009, 50(7): 1028-1035. doi: 10.2967/jnumed.108.058495 |
[5]
|
Song SL, Liu JJ, Huang G, et al. Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model. J Nucl Med, 2008, 49(2): 303-309. doi: 10.2967/jnumed.107.044206 |
[6]
|
Brepoels L, Stroobants S, Verhoef G, et al. 18F-FDG and18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med, 2009, 50(7): 1102-1109. doi: 10.2967/jnumed.109.062208 |
[7]
|
Dose SJ, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med, 2005, 46(7): 1144-1150. |
[8]
|
Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med, 2008, 49(7): 1038-1046. doi: 10.2967/jnumed.107.050187 |
[9]
|
Sugiyama M, Sakahara H, Sato K, et al. Evaluation of 3′-deoxy-3′-18F-Fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med, 2004, 45(10): 1754-1758. |
[10]
|
Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med, 2005, 46(1): 114-120. |
[11]
|
Oyama N, Ponde DE, Dence C, et al. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med, 2004, 45(3): 519-525. |
[12]
|
Pan MH, Huang SC, Liao YP, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol, 2008, 10(6): 325-334. doi: 10.1007/s11307-008-0158-z |
[13]
|
Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation invivowith[F-18]FLTandpositron emission tomography. Nat Med, 1998, 4(11): 1334-1336. doi: 10.1038/3337 |
[14]
|
Turcotte E, Wiens LW, Grierson JR, et al. Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F]fluorothymidine(18F-FLT)for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med, 2007, 7: 3. doi: 10.1186/1471-2385-7-3 |
[15]
|
Waarde AV, Cobben DCP, Suurmeijer AJH, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med, 2004, 45(4): 695-700. |
[16]
|
Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med, 2002, 43(9): 1210-1217. |
[17]
|
Direcks WG, Berndsen SC, Proost N, et al. [18F]FDG and[18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer, 2008, 99(3): 481-487. doi: 10.1038/sj.bjc.6604523 |
[18]
|
Wang H, Liu B, Tian JH, et al. Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice. World J Gastroenterol, 2010, 16(43): 5416-5423. doi: 10.3748/wjg.v16.i43.5416 |
[19]
|
Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol, 1988, 27(2): 131-146. doi: 10.3109/02841868809090333 |
[20]
|
Langen AJ, Klabbers B, Lubberink M, et al. Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging, 2009, 36(3): 389-395. doi: 10.1007/s00259-008-0960-5 |
[21]
|
Muzi M, Mankoff DA, Grierson JR, et al. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med, 2005, 46(2): 371-380. |
[22]
|
Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med, 2005, 46(2): 274-282. |
[23]
|
Muzi M, Spence AM, Sullivan F, et al. Kinetic analysis of 3′-deoxy-3′- 18F-fluorothymidinein patients with gliomas. J Nucl Med, 2006, 47(10): 1612-1621. |
[24]
|
Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med, 2003, 44(9): 1426-1431. |
[25]
|
Cobben DC, van der Laan BF, Maas B, et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med, 2004, 45(2): 226-231. |
[26]
|
van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of 18FFLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med, 2005, 46(3): 400-404. |
[27]
|
Leyton J, Latigo JR, Perumal M, et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res, 2005, 65(10): 4202-4210. doi: 10.1158/0008-5472.CAN-04-4008 |
[28]
|
Jensen MM, Erichsen KD, Bjorkling F, et al. Early detection of response to experimental chemotherapeutic Top216 with[18F]FLT and[18F]FDG PET in human ovary cancer xenografts in mice. PLoSONE, 2010, 5(9): e12965. doi: 10.1371/journal.pone.0012965 |
[29]
|
Apisarnthanarax S, Alauddin MM, Mourtada F, et al. Early detection of chemoradioresponse in esophageal carcinomaby3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res, 2006, 12(15): 4590-4597. doi: 10.1158/1078-0432.CCR-05-2720 |
[30]
|
Wang H, Zhang JM, Tian JH, et al. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med, 2009, 50(11): 1857-1864. doi: 10.2967/jnumed.109.064238 |
[31]
|
Troost EG, Bussink J, Aswin L, et al. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med, 2010, 51(6): 866-874. doi: 10.2967/jnumed.109.069310 |
[32]
|
Dittmann H, Dohmen BM, Paulsen F, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging, 2003, 30(10): 1407-1412. doi: 10.1007/s00259-003-1257-3 |
[33]
|
Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med, 2005, 46(6): 945-952. |
[34]
|
Ecke F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med, 2009, 50(9): 1441-1447. doi: 10.2967/jnumed.109.065896 |
[35]
|
Tian JH, Yang XF, Yu LJ, et al. A Multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3-deoxy-3-18F-fluorothymidine and 18F-FDG. J Nucl Med, 2008, 49(2): 186-194. doi: 10.2967/jnumed.107.044966 |